Novel external agent
The present invention relates to a transdermal administration preparation for external application such as ointment, cream and the like, which contains SMP-114 or leflunomide or a pharmaceutically acceptable acid addition salt thereof as an active ingredient. The present invention further relates to a pharmaceutical composition for transdermal administration which contains, a) as an active ingredient, N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide or an active motabolite thereof or a pharmaceutically acceptable salt thereof; and B)(1) a carrier for transdermal administration which contains a base for dissolution in a proportion of not less than 40 w/w %, or (2) a carrier for transdermal administration which contains a hydrophobic base for suspension having no polar group in a molecule in a proportion of not less than 70 w/w %. According to the present invention, a novel means of transdermal administration of SMP-114 or leflunomide or an active motabolite thereof or a pharmaceutically acceptable acid addition salt thereof can be provided.
1 . A dosage form for external application comprising an isoxazole derivative having two substituents as an active ingredient.
2 . The dosage form for external application of claim 1 , wherein the isoxazole derivative is SMP-114 or a pharmaceutically acceptable acid addition salt thereof.
3 . The dosage form for external application of claim 1 , wherein the isoxazole derivative is leflunomide.
4 . The dosage form for external application of claim 1 , which is an ointment or cream.
5 . The dosage form for external application of claim 1 , which is a solution.
6 . The dosage form for external application of claim 2 , wherein an amount of SMP-114 is 0.1-10 w/w %.
7 . The dosage form for external application of claims 2 , wherein an amount of SMP-114 is 0.2-5 w/w %.
8 . The dosage form for external application of claim 3 , wherein an amount of leflunomide is 0.1-10 w/w %.
9 . The dosage form for external application of claim 3 , wherein an amount of leflunomide is 0.2-5 w/w %.
10 . A pharmaceutical composition for transdermal administration, which comprises SMP-114 or a pharmaceutically acceptable acid addition salt thereof as an active ingredient.
11 . A pharmaceutical composition for transdermal administration, which comprises a) leflunomide or an active motabolite thereof, or a pharmaceutically acceptable salt thereof as an active ingredient; and
b)(1) a carrier for transdermal administration, which comprises a base for dissolution in a proportion of not less than 40 w/w %, or
(2) a carrier for transdermal administration, which comprises a hydrophobic base for suspension, having no polar group in a molecule, in a proportion of not less than 70 w/w %.
12 . The pharmaceutical composition of claim 11 , wherein the active metabolite is N-(4-trifluoromethylpheyl)-2-cyano-3-hydroxy-crotonamide.
13 . The pharmaceutical composition of claim 11 , which is an active ingredient dissolution type composition, wherein the carrier for transdermal administration comprises a base for dissolution in a proportion of not less than 40 w/w %.
14 . The pharmaceutical composition of claim 13 , wherein the base for dissolution is one kind of base or a mixture of two or more kinds thereof selected from dibasic acid dialkyl esters, polyoxyethylene polyoxypropylene glycols, medium chain fatty acid triglycerides and macrogols.
15 . The pharmaceutical composition of claim 13 , wherein the carrier for transdermal administration has a hydrocarbon oil content of not more than 40 w/w %.
16 . The pharmaceutical composition of claim 13 , wherein the carrier for transdermal administration has a content of the base for dissolution of not less than 50 w/w %.
17 . The pharmaceutical composition of claim 13 , wherein the carrier for transdermal administration further comprises a lipophilic nonionic surfactant.
18 . The pharmaceutical composition of claim 14 , wherein the dibasic acid dialkyl ester is one kind of said ester or a mixture of two or more kinds thereof selected from diethyl sebacate, diisopropyl sebacate and diisopropyl adipate.
19 . The pharmaceutical composition of claim 14 , wherein the polyoxyethylene polyoxypropylene glycol is one kind of said glycol or a mixture of two or more kinds thereof selected from those that are liquid at 30° C.
20 . The pharmaceutical composition of claim 14 , wherein the medium chain fatty acid triglyceride is one kind of said triglyceride or a mixture of two or more kinds thereof selected from triglycerides comprising a fatty acid having 8 to 10 carbon atoms.
21 . The pharmaceutical composition of claim 17 , wherein the lipophilic nonionic surfactant is α-monoalkyl glyceryl ether.
22 . The pharmaceutical composition of claim 17 , wherein the carrier for transdermal administration has a lipophilic nonionic surfactant content of 0.1-10 w/w %.
23 . The pharmaceutical composition of claim 13 , which has a dosage form of a solution, an ointment, a gel preparation or a plaster.
24 . The pharmaceutical composition of claim 13 , which has a dosage form of a solution, an ointment or a gel preparation.
25 . The pharmaceutical composition of claim 11 , wherein the carrier for transdermal administration comprises a hydrophobic base for suspension, having no polar group in a molecule, in a proportion of not less than 70 w/w %, and the composition comprises the active ingredient stably suspended in the carrier.
26 . The pharmaceutical composition of claim 25 , wherein the hydrophobic base for suspension is a hydrocarbon oil.
27 . The pharmaceutical composition of claim 25 , wherein the hydrophobic base for suspension is a hydrocarbon gel.
28 . The pharmaceutical composition of claim 25 , wherein the carrier for transdermal administration consists only of a hydrophobic base for suspension having no polar group in a molecule.
29 . The pharmaceutical composition of claim 25 , wherein all the active ingredient particles suspended in the carrier for transdermal administration substantively have a particle size of not more than 100 μm and the average particle size is not more than 20 μm.
30 . The pharmaceutical composition of claim 25 , wherein all the active ingredient particles suspended in the carrier for transdermal administration substantively have a particle size of not more than 20 μm and the average particle size is not more than 10 μm.
31 . The pharmaceutical composition of claim 25 , which has a dosage form of an ointment, a liquid or a plaster.
32 . The pharmaceutical composition of claim 25 , which has a dosage form of a suspended ointment or a suspended liquid.
33 . The pharmaceutical composition of claim 11 , which comprises the active ingredient in a proportion of 0.1-10 w/w %.
34 . Use of leflunomide or an active motabolite thereof, or a pharmaceutically acceptable salt thereof for the production of a transdermally administered therapeutic agent for chronic rheumatism or arthritis, which comprises a composition for transdermal administration of claim 1 .
35 . An administration method for the treatment of chronic rheumatism or arthritis, which comprises transdermally administering a pharmaceutical composition for transdermal administration, which comprises
a) leflunomide or an active motabolite thereof, or a pharmaceutically acceptable salt thereof as an active ingredient; and
b)(1) a carrier for transdermal administration, which comprises a base for dissolution in a proportion of not less than 40 w/w %, or
(2) a carrier for transdermal administration, which comprises a hydrophobic base for suspension having no polar group in a molecule in a proportion of not less than 70 w/w %.
36 . The administration method of claim 35 , wherein the carrier for transdermal administration comprises a base for dissolution in a proportion of not less than 40 w/w %, and the active ingredient is transdermally administered in a dissolution state in the carrier for transdermal administration.